阿尼卡疗法 ANIK 深 沪
已收盘 12-19 16:00:00 美东时间
9.58
+0.030
+0.31%
华盛通- 最 高10.135
- 今 开9.54
- 成交量 27.62万股
- 最 低 9.36
- 昨 收 9.55
- 总市值 1.39亿
- 52周最高 18.37
- 市盈率 静 33.91
- 换手率 1.90%
- 52周最低 7.90
- 委 比 -17.50%
- 总股本 1454.39万
- 历史最高 75.715
- 量 比 1.36
- 振 幅 8.12%
- 历史最低 1.10
- 每 手 1
- 风险率 3.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics granted 2,500 stock options to a new employee at $11.45 per share, vesting annually over three years, under its 2021 Inducement Plan.
06-05 21:00
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
ANI Pharmaceuticals' CEO, Nikhil Lalwani, will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 2:35pm ET. The live and archived webcast will be available on the Company’s website under the Investors section.
05-27 20:30
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
ANI Pharmaceuticals announced a Phase 4 clinical trial comparing two dose levels of Purified Cortrophin Gel for treating acute gout flares, evaluating safety and efficacy.
05-22 10:50
